Clinical trials: Healthy Male
Diabetes Mellitus, Type 2
A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects
The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of multiple oral doses of DBPR108 in healthy male subjects.
- Trial name
- NCT02163278
- Testing
- DBPR108
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Trial name
- NCT03719443
- Testing
- VIS649
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Fasting
Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions
To assess the bioequivalence of lamotrigine from Lamotrigin Desitin 100 mg tablets and Lamictal 100 mg Tablet.
- Trial name
- NCT06199791
- Testing
- Lamotrigine 100 MG
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Desitin Arzneimittel GmbH
Healthy
Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III
To evaluate the PK/PD of single injected human ATIII Products, SKATIII and ATIII, phase1 study in healthy male subjects was designed
- Trial name
- NCT00846274
- Testing
- SK Antithrombin III
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Parkinson Disease
Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers
No clinical trials with PBF-509 in humans have been performed to date. Only preclinical studies have been done to assess the pharmacology and pharmacokinetics, the safety and the toxicological profile of the PBF-509.
- Trial name
- NCT01691924
- Testing
- PBF-509
- Where
- 2 sites in Spain
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Healthy
Multiple Ascending Dose Study of GLPG0974 in Healthy Subjects
The purpose of this study is to evaluate the safety and tolerability after multiple ascending oral doses of GLPG0974 given to healthy male subjects for 14 days, compared to placebo.
- Trial name
- NCT01721980
- Testing
- GLPG0974
- Where
- Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Drug Interactions
An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
The purpose of this study is to evaluate the effects of steady-state telotristat ethyl on the pharmacokinetics (PK) of single-dose fexofenadine in healthy subjects.
- Trial name
- NCT02157558
- Testing
- Fexofenadine, Telotristat etiprate
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Healthy
Whole Body Vibration Training for Pelvic Floor Muscle
To study which position on the whole body vibrator machine would stimulate the pelvic floor muscles.
- Trial name
- NCT02341976
- Testing
- Vibratory platform exercises
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Minnesota
Healthy Male and Female Subjects
The Effect of Cycling, Running, and Playing Rugby on Three Biomarkers That May Indicate Brain Injury
The goal of this clinical trial was to determine if and how the biomarkers neurofilament light (NfL), brain lipid binding protein (BLBP), and amyloid precursor protein (APP) accumulated over 72 hours in venous blood following…
- Trial name
- NCT06804291
- Testing
- Running, Cycling, Rugby
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Appalachian State University
Congenital Bleeding Disorder, Haemophilia A
Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the bioequivalence of eptacog alfa A 6 mg and NovoSeven® in healthy male subjects.
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B
- Trial name
- NCT02084810
- Testing
- activated recombinant human factor VII, eptacog alfa (activated)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Renal Impairment
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects
- Trial name
- NCT01558323
- Testing
- LCQ908
- Where
- 2 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pharmacokinetic Study in Healthy Male Volunteers
A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers
A Phase 1 study to assess the effect of itraconazole, a strong inhibitor of CYP3A and P-glycoprotein, on the pharmacokinetics (PK) of orvepitant in healthy male volunteers.
- Trial name
- NCT03535662
- Testing
- Orvepitant, Itraconazole
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nerre Therapeutics Ltd.
Rheumatoid Arthritis
A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject
HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic structure of biguanide in metformin, an existing diabetes drug. The immune modulating activity of HL237 was demonstrated in animal model.
- Trial name
- NCT03278470
- Testing
- HL237
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Healthy
A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body
This trial intends to investigate the basic pharmacokinetics of BI 425809 and [14C]- radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of 25 mg BI 425809 (C-14) given to healthy…
- Trial name
- NCT03654170
- Testing
- BI 425809 mixed with [C-14] BI425809
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects
The goals of this study are to evaluate the safety and tolerability of multiple ascending doses of PF-04634817 administered orally to healthy adult subjects.
- Trial name
- NCT01140672
- Testing
- PF-04634817
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529
This phase I study is to assess the mass balance recovery after a single oral dose of [14C]-AK0529 in healthy male subjects.
- Trial name
- NCT03400995
- Testing
- AK0529
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Healthy
Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.
Investigation of food effect on the bioavailability of a 25 mg empagliflozin tablet and assessment of dose proportionality between 10 mg and 25 mg empagliflozin tablets under fasting conditions.
- Trial name
- NCT01451775
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants
The purpose of the study is to assess mass balance, biotransformation, and excretion of BMS-986369 following study drug administration.
- Trial name
- NCT05567510
- Testing
- BMS-986369
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers, Down Syndrome
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
Leucettinib-21 First-in-Human Phase 1 Study in 6 Parts: Single (Part 1 and 5) and Multiple (Part 3 and 6) Ascending Doses, and Food-Effect (Part 2) in Healthy Subjects, and Single Dose (Part 4) in People with Down Syndrome (DS)…
- Conditions
- Healthy Volunteers, Down Syndrome, Alzheimer's Disease
- Trial name
- LEUCETTA (NCT06206824)
- Testing
- Leucettinib-21
- Where
- France
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Perha Pharmaceuticals
Healthy
A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy Japanese male participants after single and multiple oral dose administration.
- Trial name
- NCT03564379
- Testing
- JNJ-42165279
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.